scorecardresearch
Follow Us:
Saturday, July 31, 2021

Johnson & Johnson in discussion with FDA regarding COVID-19 vaccine side effects

The chance of having Guillain-Barré syndrome occur is very low and the rate of reported cases exceeds the background rate by a small degree, J&J said.

By: Reuters |
Updated: July 13, 2021 12:21:04 pm
Johnson & Johnson in discussion with FDA regarding COVID-19 vaccine side effectsJohnson & Johnson said on Monday it was in discussions with the US Food and Drug Administration about rare cases of a neurological disorder that have been reported following vaccination with the Janssen COVID-19 vaccine. (Reuters file photo)

Johnson & Johnson said on Monday it was in discussions with the US Food and Drug Administration about rare cases of a neurological disorder, Guillain-Barré syndrome, that have been reported following vaccination with the Janssen COVID-19 vaccine.

The chance of having Guillain-Barré syndrome occur is very low and the rate of reported cases exceeds the background rate by a small degree, J&J said.

The statement follows a Washington Post report on Monday, which said the FDA was expected to announce a new warning on J&J’s coronavirus vaccine related to a rare autoimmune disorder.

Guillain-Barré syndrome is a rare neurological disorder in which the body’s immune system mistakenly attacks part of its peripheral nervous system or the network of nerves located outside of the brain and spinal cord.

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest World News, download Indian Express App.

  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement

Advertisement
Advertisement
Advertisement